CAR-T

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview of the current development of […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As 4 February was World Cancer Day, this week’s update focused on developments in the field of oncology. Drugs for lung cancer, lymphoma […]

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer.  As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will allow the development of a novel approach to treating tumours, and […]

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS.  Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Cell and gene therapies have been making the news this week, as we launch our very own guide to global innovation in CGT with the Winter […]

News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer. Cell and gene therapies have been making the news this week, as we launch our very own guide to global innovation in CGT with the Winter issue of DDW, as well as an exciting new virtual event on the same topic.  The top stories:  Gene […]

CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen’s BCMA CAR-T product CT053 in mainland China.  CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen’s lead drug candidate and an autologous CAR T-cell product treating relapsed/refractory multiple myeloma (R/R MM).  Dr Zonghai Li, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer […]

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this new on-demand webinar, Twist Bioscience’s CSO, Aaron Sato, will present […]

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this webinar, Twist Bioscience’s CSO, Aaron Sato, will present several proof-of-concept […]

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month.   Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening to read in the Guardian1 […]

CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity, according to the results of a new study in mice with an autoimmune disease similar to multiple sclerosis (MS).  CAR-T, which uses genetically altered immune cells to destroy cancer cells, has revolutionised treatment of some blood cancers since it was introduced in 2017.  […]

This 28-page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many pathways Access the eBook here

This latest 28 page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many pathways

Alongside industry professionals interested in the cell and gene therapy landscape in Europe, DDW’s Multimedia Editor Megan Thomas was welcomed to Advanced Therapies Europe 2022 by Phacilitate’s Vice President, Becky Johnson-Kent. Johnson-Kent introduced the notion of the zebra company and compared its two-fold purpose of profitability and societal advancement to the cell and gene therapy industry. […]

The European Commission (EC) has approved biotechnology company Kite’s CAR T-cell therapy Yescarta for patients with follicular lymphoma (FL).  Specifically the approval is for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.  The approval was based on data from the ongoing single-arm Phase II  ZUME-5 study […]

News round-up by DDW’s Reece Armstrong for 6-10 June Antibiotic developments, vaccines for MMR and business expansions are some of the features of this week’s news round-up. US gets another MMR vaccine option in GSK’s Priorix   GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been approved by the US FDA, the […]